Yuyu Pharma, Inc. (KRX:000220)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,885.00
+45.00 (1.17%)
Last updated: Sep 1, 2026, 1:19 PM KST

Yuyu Pharma Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
144,371140,885133,147137,210138,881115,655
Other Revenue
-0-0-0-0-0-
144,371140,885133,147137,210138,881115,655
Revenue Growth
6.69%5.81%-2.96%-1.20%20.08%17.87%
Cost of Revenue
88,68487,29981,77888,68285,91570,567
Gross Profit
55,68653,58651,36948,52752,96645,088
Selling, General & Admin
37,15536,89734,19037,97243,02837,270
Research & Development
3,5533,6132,7807,1888,6204,008
Amortization of Goodwill & Intangibles
462.3520.3627.2626.13507.58376.08
Other Operating Expenses
172.31239.81212.88219.22221.25258.87
Operating Expenses
42,52542,56738,78849,27653,55943,888
Operating Income
13,16211,01912,582-748.94-592.111,200
Interest Expense
-1,998-2,481-3,218-2,554-2,581-2,175
Interest & Investment Income
1,1791,1621,066990.69605.88216.83
Earnings From Equity Investments
545.07571.4368.58-493.69395.07548.18
Currency Exchange Gain (Loss)
-165.67-584.74-150.09-23.86-478.1256.72
Other Non Operating Income (Expenses)
-394.561,078-892.12-2,592-852.87-87.18
EBT Excluding Unusual Items
12,32810,7659,456-5,422-3,503-240.68
Gain (Loss) on Sale of Investments
-1,153-267.07-370.71657.78182.69-139.24
Gain (Loss) on Sale of Assets
17.0316.71,24963.45-46.08-3.23
Asset Writedown
---349.46-741.5-444.09-
Other Unusual Items
1,934-1,032----
Pretax Income
13,1269,4839,985-5,442-3,810-383.16
Income Tax Expense
695.22365.96-304.6798.44615.02537.13
Earnings From Continuing Operations
12,4309,11710,289-5,541-4,425-920.29
Minority Interest in Earnings
73.42-962.7-1,569-1,640-1,562-1,294
Net Income
12,5048,1548,720-7,181-5,988-2,214
Preferred Dividends & Other Adjustments
323.74323.74--878.27284.89284.89
Net Income to Common
12,1807,8308,720-6,303-6,273-2,499
Net Income Growth
139.08%-10.21%----
Shares Outstanding (Basic)
151617161716
Shares Outstanding (Diluted)
202017161716
Shares Change
10.81%18.27%4.49%-1.89%3.90%32.81%
EPS (Basic)
808.62492.34520.00-387.43-378.31-156.57
EPS (Diluted)
695.09481.00513.00-387.43-378.31-157.00
EPS Growth
148.35%-6.24%----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
6,0267,62517,838-4,094-11,512-1,565
Free Cash Flow Per Share
298.74379.231049.38-251.63-694.28-98.04
Gross Margin
38.57%38.04%38.58%35.37%38.14%38.98%
Operating Margin
9.12%7.82%9.45%-0.55%-0.43%1.04%
Profit Margin
8.44%5.56%6.55%-4.59%-4.52%-2.16%
Free Cash Flow Margin
4.17%5.41%13.40%-2.98%-8.29%-1.35%
EBITDA
18,81416,62718,2484,8584,4355,703
EBITDA Margin
13.03%11.80%13.71%3.54%3.19%4.93%
D&A For EBITDA
5,6535,6085,6665,6075,0274,503
EBIT
13,16211,01912,582-748.94-592.111,200
EBIT Margin
9.12%7.82%9.45%-0.55%-0.43%1.04%
Effective Tax Rate
5.30%3.86%----
Advertising Expenses
-2,2272,6954,4817,1196,131